<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02067858</url>
  </required_header>
  <id_info>
    <org_study_id>10-003</org_study_id>
    <nct_id>NCT02067858</nct_id>
  </id_info>
  <brief_title>An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System</brief_title>
  <official_title>An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steven Burton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this clinical research are to evaluate the outcomes and tumor response for early&#xD;
      stage non-small lung cancer (NSCLC) patients undergoing Stereotactic Body Radiation Therapy&#xD;
      (SBRT) using four dimensional (4D) Positron Emission Tomography (PET) and Computed Tomography&#xD;
      (CT), Cone-Beam Computed Tomography (CBCT), Real-Time Position Management (RPM™) and body&#xD;
      immobilization system (see figure 1). Specifically, the effect of image-guided SBRT treatment&#xD;
      on clinical tumor response rate, local control and progression-free survival will be studied.&#xD;
      This study will examine target volumes and relevant margins determined by an assessment using&#xD;
      4D PET and repeated 4D CT. These data will allow us to evaluate and determine the impact of&#xD;
      the body immobilization system on the planning target volume (PTV) margins, patient's&#xD;
      breathing pattern, target motion, and inter-treatment targets shifts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Clinical Response Rate and Local Control Following SBRT Treatment of Patients With Early Stage NSCLC</measure>
    <time_frame>2 years</time_frame>
    <description>The Number of Patients that completed SBRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients with Progression Free Survival at 2 Years</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of Imaging Response With Serum Protein and Peptide Profiles</measure>
    <time_frame>2 years</time_frame>
    <description>Research blood draws looking at imaging repsonse before and after radiation in relationship to serum protein and peptide profiles</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>4D CT</condition>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 fractions x 20 Gy 4 fractions x 12 Gy&#xD;
Lesion dependent</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <arm_group_label>Stereotactic Radiosurgery</arm_group_label>
    <other_name>SBRT</other_name>
    <other_name>SRS</other_name>
    <other_name>Trilogy</other_name>
    <other_name>True Beam</other_name>
    <other_name>Cyber Knife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The patient must be over the age of 18 years. Histologic confirmation of primary NSCLC of&#xD;
        the lung tumor must be complete prior to SBRT treatment.&#xD;
&#xD;
        The following stages of NSCLC patients would be eligible for the study:&#xD;
&#xD;
        Stage I:&#xD;
&#xD;
        T1 N0 M0 T2 N0 M0 (Size ≤ 5 cm)&#xD;
&#xD;
        Stage II:&#xD;
&#xD;
        T3 N0 M0 (Chest wall invasion only, Size ≤ 5 cm)&#xD;
&#xD;
        Staging Tumor size and characteristics: they will be determined by PET-CT scan&#xD;
&#xD;
        Nodal disease:&#xD;
&#xD;
        Patients with chest CT scan demonstrating hilar or mediastinal nodes &lt;1cm and/or PET&#xD;
        negative would be considered N0 disease.&#xD;
&#xD;
        Patients who have hilar or mediastinal nodes &gt; 1 cm and PET scan negative may be considered&#xD;
        N0 disease.&#xD;
&#xD;
        If PET scan demonstrates suspicious uptake or abnormal uptake, these patients would be&#xD;
        eligible, if a directed biopsy (by mediastinoscopy, Chamberlein procedure or other&#xD;
        modalities such as trans-bronchial biopsy, CT guided biopsy) is negative.&#xD;
&#xD;
        Metastases:&#xD;
&#xD;
        Evaluated by PET-CT scanning and biopsy as indicated&#xD;
&#xD;
        The patient must have an ECOG/Zubrod performance status of 0, 1, or 2. In order to be&#xD;
        considered medically-inoperable, the patient must meet at least one major criterion or meet&#xD;
        a minimum of 2 minor criteria as described below.&#xD;
&#xD;
        MAJOR CRITERIA:&#xD;
&#xD;
        FEV1 &lt; 50% or predicted postoperative FEV1 &lt; 40% DLCO &lt; 50% or predicted postoperative DLCO&#xD;
        &lt; 40% Exercise induced maximal exercise oxygen consumption (MVO2)&lt;15 ml/kg/min Thoracic&#xD;
        surgery consultation should be obtained from a Board Certified Thoracic surgeon who in&#xD;
        collaboration with a radiation oncologist should determine if the patient is medically&#xD;
        operable This criterion would be mandatory&#xD;
&#xD;
        MINOR CRITERIA:&#xD;
&#xD;
        Age &gt; 80 Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater&#xD;
        than 40mm Hg) Oxygen requirement (using the Medicare criteria for home oxygen requirements&#xD;
        [i.e., room air oxygen saturation of 88% or less]) Congestive heart failure (any three of&#xD;
        the following must be documented: dyspnea, peripheral edema, chest x-ray with interstitial&#xD;
        edema or cardiomegaly, rales, or congestion) Poor left ventricular function (defined as an&#xD;
        ejection fraction of 40% or less) Severe cerebral (with CVA or recent TIA) or severe&#xD;
        peripheral vascular disease Diabetes Mellitus with severe organ damage such as End-Stage&#xD;
        Renal Disease (ESRD), Blindness, Vascular disease.&#xD;
&#xD;
        CBC, Diff and platelets, Comprehensive metabolic panel within 28 days of registration&#xD;
        meeting the following criteria&#xD;
&#xD;
        leukocytes &gt;3,000/mcL absolute neutrophil count &gt;1,500/mcL hemoglobin &gt;9 g/dL (hemoglobin&#xD;
        may be supported by transfusion or erythropoietin or other approved hematopoietic growth&#xD;
        factors) platelets &gt;100,000/mcL total bilirubin &lt;1.5x institutional upper limit of normal&#xD;
        creatinine within normal institutional limits OR creatinine clearance &gt;60 mL/min/1.73 m2&#xD;
        for patients with creatinine levels above institutional normal.&#xD;
&#xD;
        Females of child-bearing age must be using a reliable form of birth control. The patient&#xD;
        must provide a signed and dated written informed consent PRIOR to registration and prior to&#xD;
        undergoing any study-related procedures.&#xD;
&#xD;
        The patient must provide written authorization to allow for the use and disclosure of their&#xD;
        protected Health information.&#xD;
&#xD;
        Conditions for Patient Ineligibility The patient's weight exceeds the tolerances of the&#xD;
        institution's imaging and treatment platform/couch.&#xD;
&#xD;
        The patient has received thoracic radiation therapy in the same region as the current SBRT&#xD;
        planned treatment area. The patient has completed chemotherapy within 30 days of treatment.&#xD;
        T2: Tumor size &gt; 5 cm, T3 tumors (except T3 by virtue of chest wall invasion and ≤ 5cm), T4&#xD;
        tumors. Presence of N1, N2 or N3 disease per previously described criteria would also be&#xD;
        excluded.&#xD;
&#xD;
        Pancoast tumors would be excluded. Current distant metastatic disease (M1) (preferably&#xD;
        biopsy proven). The patient is a female with child-bearing potential who refuses to obtain&#xD;
        a serum pregnancy test prior to the initiation of treatment.&#xD;
&#xD;
        The patient is pregnant or a female who is nursing an infant. The patient is planning on&#xD;
        undergoing systemic therapy within 2 weeks after the last fraction of radiation The patient&#xD;
        has an active systemic or pulmonary infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight E Heron, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Shadyside Radiation Oncology Department</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <results_first_submitted>December 4, 2017</results_first_submitted>
  <results_first_submitted_qc>June 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 18, 2018</results_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Steven Burton</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stereotactic Radiosurgery</title>
          <description>3 fractions x 20 Gy 4 fractions x 12 Gy&#xD;
Lesion dependent&#xD;
Stereotactic Radiosurgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stereotactic Radiosurgery</title>
          <description>3 fractions x 20 Gy 4 fractions x 12 Gy&#xD;
Lesion dependent&#xD;
Stereotactic Radiosurgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess Clinical Response Rate and Local Control Following SBRT Treatment of Patients With Early Stage NSCLC</title>
        <description>The Number of Patients that completed SBRT</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery</title>
            <description>3 fractions x 20 Gy 4 fractions x 12 Gy&#xD;
Lesion dependent&#xD;
Stereotactic Radiosurgery</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Clinical Response Rate and Local Control Following SBRT Treatment of Patients With Early Stage NSCLC</title>
          <description>The Number of Patients that completed SBRT</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Progression-free Survival</title>
        <description>Number of patients with Progression Free Survival at 2 Years</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery</title>
            <description>3 fractions x 20 Gy 4 fractions x 12 Gy&#xD;
Lesion dependent&#xD;
Stereotactic Radiosurgery</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Progression-free Survival</title>
          <description>Number of patients with Progression Free Survival at 2 Years</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of Imaging Response With Serum Protein and Peptide Profiles</title>
        <description>Research blood draws looking at imaging repsonse before and after radiation in relationship to serum protein and peptide profiles</description>
        <time_frame>2 years</time_frame>
        <population>Blood draw samples were not drawn nor analyzed for this study</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery</title>
            <description>3 fractions x 20 Gy 4 fractions x 12 Gy&#xD;
Lesion dependent&#xD;
Stereotactic Radiosurgery</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Imaging Response With Serum Protein and Peptide Profiles</title>
          <description>Research blood draws looking at imaging repsonse before and after radiation in relationship to serum protein and peptide profiles</description>
          <population>Blood draw samples were not drawn nor analyzed for this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stereotactic Radiosurgery</title>
          <description>3 fractions x 20 Gy 4 fractions x 12 Gy&#xD;
Lesion dependent&#xD;
Stereotactic Radiosurgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Holeva</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-623-1275</phone>
      <email>holevakd@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

